https://www.marketscreener.com/quote/stock/BEIGENE-LTD-26123632/news/BeiGene-Announces-First-Patient-Dosed-in-Global-Phase-3-Trial-of-Anti-TIGIT-Antibody-Ociperlimab-i-35631657/?utm_source=telegram&utm_medium=social&utm_campaign=share